Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2006

View Archived Issues

Radius acquires rights to ER-beta selective compounds

Reimbursement progress for cintredekin besudotox

Series A financing at Cabrellis to fund development of Calsed

Second analytical method validated for PT-401

Neose Technologies receives research milestone payment from Novo Nordisk

QR-443 prevents cachexia in mice

rHuPH20 studied for absorption enhancement of large molecule protein therapeutic

Shire makes strides in second quarter

Phase I findings for AZD-103

Phase II trial of FM-VP4 on schedule

Combining immunotherapies with antitumor agents for the treatment of metastatic renal cell carcinoma

Second phase III trial of Sativex in central neuropathic pain due to MS

Biota receives award for development of Flunet compounds

Findings of investigation into patient death in phase II DAC:GRF trial

Withdrawal of E.U. marketing authorization for Fortovase

WX-671 begins study in cancer patients

Epigenomics enters into R&D agreement with J&J

Immunicon enters into agreements with AstraZeneca

Homer-1a: a novel target for pain therapeutics

Novel therapeutic agents for respiratory disorders disclosed in recent patents

New therapeutic agents for metabolic disorders reported in recent patent literature

Novel P2Y1 receptor antagonists for thrombotic disorders emerge from Bristol-Myers Squibb R&D

Activation of EGFR in optic nerve astrocytes mediates optic nerve damage in rats

Augmentation strategy with memantine for resistant depression to be evaluated in clinical study

Ophthalmic ciclosporin to be tested for the treatment of ocular rosacea in new clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...